Clinical Trial Detail

NCT ID NCT02879760
Title Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Turnstone Biologics, Inc.
Indications

lung non-small cell carcinoma

Therapies

Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.